Overview


A method that identifies the entire DNA or RNA sequence of cancer cells using the sequencing of one, homogeneous, or heterogeneous tumor cell group. This is called cancer genome sequencing. This laboratory technique characterizes the DNA or RNA sequences in primary tumor tissue and tumor microenvironment (such as stromal/fibroblast cells), surrounding normal tissue, and metastatic tumor sites. This technique provides information about the identification of nucleotide bases (DNA or RNA), mutation status, copy numbers, sequence variants, and structural variations, including fusion genes, chromosomal translocations, and copy numbers. This technology has been a breakthrough in the fight against breast cancer. It allows for individualization of treatment. The market is growing due to the rapid development of new methods and a decrease in the cost of genome sequencing. The global cancer genome sequencing market will grow at a healthy CAGR thanks to technological advancements and the entry of new market players. Agilent Technologies and GE Healthcare Life Sciences, Johnson
Johnson are just a few of the major players in this market.
Recent advancements in computing power are key factors that drive global genome sequencing market demand. This supports growth in the genome sequencing industry and gives rise to faster technologies. The process is more accessible and cheaper because of the speed improvements in computing power. The global genome sequencing market is expected to grow due to the growing applications of genome sequencing in anticancer treatment and pharmacogenomics. The rise in cancer, the increasing emergence of genomic medicine as a treatment option, and recent advances in genomics have led to an increase in Genomics in Cancer Care. The target market has seen a wide range of applications in Gene Therapy and Gene Discovery, Personalized Medicine Pharmacogenetics
Targeted Therapy Metagenomics, Mitochondrial genomics, Pharmacogenomics, and Pharmacogenomics. The Genomics in Cancer Care market is expected to benefit from the increased awareness of cancer genomics and rapid growth in the biotechnology industry, research institutes, and diagnostic centers. The importance of Genomics in cancer treatment has allowed for effective treatment, new drug development, and diagnosing and treating disease. This has boosted the market growth. Market competition is increasing and big multinational corporations as well as start-ups compete for market share.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Cancer Genome Sequencing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Cancer Genome Sequencing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

• Agilent technologies
• GE Healthcare
• Johnson
Johnson
• LI-COR Biosciences
• Abbott Laboratories
• Beckman Coulter
• Bayer Corporation
• Hamilton Thorne Biosciences
• Integrated DNA Technologies
• Microchip Biotechnologies
• Myriad Genetics
• Commonwealth Biotechnologies
• ZS Genetics
• Pacific Biosciences
(Note: The list of the major players will be updated with the latest market scenario and trends)

By Technology
• Second Generation Technology Platforms
o SOLiD Sequencing (by ABI)
o Pyro-Sequencing (by Roche)
o Bridge amplification sequencing (by Illumina)
• Third Generation Technology Platforms
o Single Molecule Real Time (SMRT) Sequencing ( by Pacific Biosciences)
o Ion Semiconductor sequencing
o Nanopore sequencing (by Oxford)
o Fluorescent Resonant energy Transfer (FRET) sequencing ( by VisiGen Biotechnologies)
By Region
• North America
• Europe
Asia-Pacific
• Latin America
• Middle East and Africa

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

• To provide with an exhaustive analysis on the Cancer Genome Sequencing Market By Technology and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Cancer Genome Sequencing Market Variables, Trends
    • Scope
        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances
  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Cancer Genome Sequencing Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Cancer Genome Sequencing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Cancer Genome Sequencing Market, By Technology Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Second Generation Technology Platforms
         1.1. SOLiD Sequencing (by ABI)
         2.2. Pyro-Sequencing (by Roche)
         1.3. Bridge amplification sequencing (by Illumina)
        2. Third Generation Technology Platforms
         2.1. Single Molecule Real Time (SMRT) Sequencing (by Pacific Biosciences)
         2.2. Ion Semiconductor sequencing
         2.3. Nanopore sequencing (by Oxford)
         2.4. Fluorescent Resonant energy Transfer (FRET) sequencing (by VisiGen Biotechnologies)
  • 8.   North America Cancer Genome Sequencing Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032
  • 9.   Latin America Cancer Genome Sequencing Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032
  • 10.   Europe Cancer Genome Sequencing Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
          2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.7. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032
  • 11.   Asia Pacific Cancer Genome Sequencing Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032
  • 12.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032
  • 13.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 14.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Agilent technologies
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. GE Healthcare
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Johnson & Johnson
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. LI-COR Biosciences
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Abbott Laboratories
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Beckman Coulter
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bayer Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Hamilton Thorne Biosciences
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Integrated DNA Technologies
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Microchip Biotechnologies
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Myriad Genetics
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Commonwealth Biotechnologies
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. ZS Genetics
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Pacific Biosciences
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview

  • 15.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 16.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients